Supplementary Figures 1-6 from Multi-substrate Metabolic Tracing Reveals Marked Heterogeneity and Dependency on Fatty Acid Metabolism in Human Prostate Cancer

Abstract

<p>Supplementary Figure 1. Metabolic profiles of prostate cancer PDX across different pathology. Supplementary Figure 2. Percent labeling of glycolysis end products and TCA cycle intermediates following 4 hours ex vivo labelling of 13C substrates. Supplementary Figure 3. Mass isotopologue distribution of malate following glucose, glutamine, palmitate, and lactate tracing. Supplementary Figure 4. PDXOs responses following metabolic inhibitors treatment. Supplementary Figure 5. Organoids viability following 7 days treatments of metabolic inhibitors. Supplementary Figure 6. Dose responses of metabolic inhibitors treatment in PDXOs.</p>